S&P 500   4,549.34
DOW   36,054.43
QQQ   385.05
14 best consumer staples dividend stocks
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
Ex dividend date vs record date: What’s the difference?
How to find blue-chip dividend stocks
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
What is the consumer staples sector?
6 best online and direct marketing retail stocks to invest in
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
Last chance to set up your portfolio for OPEC cuts
What does consumer price index measure?
S&P 500   4,549.34
DOW   36,054.43
QQQ   385.05
14 best consumer staples dividend stocks
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
Ex dividend date vs record date: What’s the difference?
How to find blue-chip dividend stocks
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
What is the consumer staples sector?
6 best online and direct marketing retail stocks to invest in
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
Last chance to set up your portfolio for OPEC cuts
What does consumer price index measure?
S&P 500   4,549.34
DOW   36,054.43
QQQ   385.05
14 best consumer staples dividend stocks
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
Ex dividend date vs record date: What’s the difference?
How to find blue-chip dividend stocks
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
What is the consumer staples sector?
6 best online and direct marketing retail stocks to invest in
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
Last chance to set up your portfolio for OPEC cuts
What does consumer price index measure?
S&P 500   4,549.34
DOW   36,054.43
QQQ   385.05
14 best consumer staples dividend stocks
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
Ex dividend date vs record date: What’s the difference?
How to find blue-chip dividend stocks
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
What is the consumer staples sector?
6 best online and direct marketing retail stocks to invest in
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
Last chance to set up your portfolio for OPEC cuts
What does consumer price index measure?

Takeda Pharmaceutical Stock Price, News & Analysis (NYSE:TAK)

$13.94
-0.03 (-0.21%)
(As of 12/6/2023 ET)
Compare
Today's Range
$13.94
▼
$14.04
50-Day Range
$13.35
▼
$15.59
52-Week Range
$13.19
▼
$17.15
Volume
1.31 million shs
Average Volume
2.22 million shs
Market Capitalization
$44.12 billion
P/E Ratio
19.36
Dividend Yield
1.79%
Price Target
$21.33
Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media

Takeda Pharmaceutical MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
53.0% Upside
$21.33 Price Target
Short Interest
Healthy
0.26% of Float Sold Short
Dividend Strength
Moderate
Based on Four Factors
Sustainability
N/A
News Sentiment
0.74mentions of Takeda Pharmaceutical in the last 14 days
Based on 3 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
118.18%
From $0.22 to $0.48 Per Share

Overall MarketRank™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

3.08 out of 5 stars

Medical Sector

25th out of 957 stocks

Pharmaceutical Preparations Industry

6th out of 399 stocks

See Top Rated MarketRank™ Stocks Here

TAK stock logo

About Takeda Pharmaceutical Stock (NYSE:TAK)

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience. The company provides its products under the Entyvio, Gattex/Revestive, Takecab/Vocinti, Alofisel, Dexilant, Pantoloc/Controloc, Adynovate/Adynovi, Feiba, Recombinate, Hemofil/Immunate/Immunine, Takhzyro, Livtencity, Elaprase, Replagal, Advate, Flexbumin, Vpriv, Gammagard Liquid/Kiovig, Hyqvia, Cuvitru, Exkivity, Ninlaro, Velcade, Azilva-F, Lotriga, Iclusig, Leuplin/Enantone, Adcetris, vyvanse/elvanse, Trintellix, and Alunbrig brands. It has in-license agreement with BioMarin, Luxna Biotech, GlaxoSmithKline, Halozyme, and Kamada; collaboration with Neurocrine Biosciences, Inc., Seagen Inc., Anima Biotech, Denali Therapeutics, KSQ Therapeutics, Noile-Immune Biotech, Center for iPS Cell Research Application, Kyoto University (CiRA), and Charles River Laboratories; licensing agreement with Mirum Pharmaceuticals and Twist Bioscience, UCSD/Fortis Advisors, PeptiDream, MD Anderson Cancer Center, Teva Pharmaceutical Industries, and Xenetic Biosciences; collaboration and licensing agreement with Arrowhead Pharmaceuticals Inc., Engitix, Genevant Sciences Corporation, Sosei Heptares, Zedira/Dr. Falk Pharma, JCR Pharmaceuticals, Exelixis, Inc., GlaxoSmithKline, Heidelberg Pharma, HUTCHMED, Presage Biosciences, Codexis, Inc., Ensoma, Envozyne, KM Biologics, and Selecta BioScience, and Ovid Therapeutics Inc.; and collaboration with ZEDIRA GmbH and Dr. Falk Pharma GmbH. It has research collaboration and licensing agreement with Crescendo Biologics, Code Bio, Immusoft, Poseida Therapeutics, and Selecta Biosciences. The company was founded in 1781 and is headquartered in Tokyo, Japan.

TAK Stock Price History

TAK Stock News Headlines

December 5, 2023 | finance.yahoo.com
Takeda and The New York Academy of Sciences Announce 2024 Innovators in Science Award Winners
December 1, 2023 | markets.businessinsider.com
Buy Rating for Harmony Biosciences Strengthened by Competitor Setbacks and Market Dynamics
December 7, 2023 | Edge On The Street (Ad)
Henry Ford Would NEVER Have Seen This Coming
In 1908, Henry Ford used a metal called vanadium in his Model T cars. Over a century later, automakers still turn to vanadium to make car bodies lighter and stronger. Today, this under-appreciated metal plays the starring role in cutting-edge battery tech set to revolutionize the energy storage market.
November 27, 2023 | msn.com
CK Hutchison-backed HutchMed eyes global expansion after FDA approval for novel cancer drug
November 27, 2023 | finance.yahoo.com
Takeda to Present Data at 65th American Society of Hematology (ASH) Annual Meeting, Demonstrating Continued Commitment to Patients with Hematologic Diseases
November 25, 2023 | morningstar.com
Takeda Pharmaceutical Co Ltd
November 22, 2023 | seekingalpha.com
TKPHF Takeda Pharmaceutical Company Limited
November 16, 2023 | finance.yahoo.com
Nikkei Falls 0.2% as Consumer, Healthcare Stocks Weigh
December 7, 2023 | Edge On The Street (Ad)
Henry Ford Would NEVER Have Seen This Coming
In 1908, Henry Ford used a metal called vanadium in his Model T cars. Over a century later, automakers still turn to vanadium to make car bodies lighter and stronger. Today, this under-appreciated metal plays the starring role in cutting-edge battery tech set to revolutionize the energy storage market.
November 10, 2023 | msn.com
Back To Back FDA Approval For Takeda Within Two Days, Secures Green Signal For Rare Blood Disorder Therapy
November 9, 2023 | finance.yahoo.com
Takeda’s ADZYNMA (ADAMTS13, recombinant-krhn) Approved by U.S. FDA as the First and Only Recombinant ADAMTS13 Enzyme Replacement Therapy for the Treatment of Congenital Thrombotic Thrombocytopenic Purpura (cTTP)
November 9, 2023 | finance.yahoo.com
UPDATE 2-Takeda Pharma gets US FDA approval for rare blood disorder therapy
November 9, 2023 | finance.yahoo.com
Takeda secures FDA approval for colon cancer drug
November 9, 2023 | investing.com
Earnings Call: Takeda Pharmaceutical’s Q2 Report Shows Modest Growth, Outlines Future Plans
November 9, 2023 | finance.yahoo.com
WAVE Life Sciences Ltd (WVE) Reports Notable Shift to Profitability in Q3 2023
November 8, 2023 | msn.com
Takeda says FDA approves its treatment for colorectal cancer
November 8, 2023 | finance.yahoo.com
Takeda Receives U.S. FDA Approval of FRUZAQLA™ (fruquintinib) for Previously Treated Metastatic Colorectal Cancer
November 1, 2023 | msn.com
Phantom Pharmaceuticals gets FDA approval for Erosive GERD drug
October 26, 2023 | marketwatch.com
Takeda Pharmaceutical Shares Slump After It Books 2Q Loss, Cuts Profit Guidance
October 26, 2023 | marketwatch.com
Takeda Pharmaceutical Books Second-Quarter Loss, Lowers Profit Guidance -- Update
October 26, 2023 | marketwatch.com
Takeda Pharmaceutical Reported Second-Quarter Loss -- Earnings Review
October 25, 2023 | markets.businessinsider.com
Takeda Pharmaceutical is about to announce its earnings — here's what Wall Street expects
October 24, 2023 | msn.com
Takeda: Why I'm Staying Bearish On This Generic Drug Dividend Play
October 24, 2023 | marketwatch.com
Takeda Pharmaceutical Expected to Post 14% Increase in Second-Quarter Net Profit -- Earnings Preview
October 20, 2023 | msn.com
EC expands Takeda’s Adcetris label for advanced Hodgkin lymphoma treatment
October 19, 2023 | markets.businessinsider.com
Catalyst Pharma Appoints Richard Daly To Succeed Patrick McEnany As CEO
October 18, 2023 | finance.yahoo.com
European Commission Approves ADCETRIS® (brentuximab vedotin) for the Treatment of Adult Patients with Previously Untreated CD30+ Stage III Hodgkin Lymphoma in Combination with AVD
See More Headlines
Receive TAK Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Takeda Pharmaceutical and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
10/26/2023
Today
12/07/2023
Next Earnings (Estimated)
2/01/2024
Fiscal Year End
3/31/2024
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NYSE
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NYSE:TAK
CUSIP
N/A
CIK
1395064
Web
www.takeda.com
Phone
(166) 204-2111
Fax
813-3278-2268
Employees
49,095
Year Founded
1781

Price Target and Rating

Average Stock Price Target
$21.33
High Stock Price Target
$30.00
Low Stock Price Target
$14.00
Potential Upside/Downside
+53.0%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
2 Analysts

Profitability

EPS (Most Recent Fiscal Year)
$0.72
Trailing P/E Ratio
19.36
Forward P/E Ratio
63.36
P/E Growth
9.03
Net Income
$2.35 billion
Net Margins
7.35%
Pretax Margin
4.75%
Return on Equity
12.36%
Return on Assets
5.74%

Debt

Debt-to-Equity Ratio
0.62
Current Ratio
1.04
Quick Ratio
0.55

Sales & Book Value

Annual Sales
$29.81 billion
Price / Sales
1.48
Cash Flow
$3.53 per share
Price / Cash Flow
3.95
Book Value
$14.86 per share
Price / Book
0.94

Miscellaneous

Outstanding Shares
3,164,780,000
Free Float
3,163,515,000
Market Cap
$44.12 billion
Optionable
Optionable
Beta
0.64

Social Links

Ten Starter Stocks For Beginners to Buy Now Cover
Ten Starter Stocks For Beginners to Buy Now

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

Key Executives

  • Mr. Christophe Weber (Age 57)
    President, CEO & Representative Director
    Comp: $3.78M
  • Mr. Constantine Saroukos (Age 52)
    CFO & Representative Director
    Comp: $2.35M
  • Dr. Andrew S. Plump (Age 58)
    President of Research & Development and Representative Director
    Comp: $2.69M
  • Dr. Seigo Izumo
    Chair of Management Board
  • Mr. Haruhiko Hirate (Age 66)
    Member of Management Board
  • Mr. Salvatore Alesci M.D. (Age 49)
    Ph.D., Member of Management Board and Head of R&D Global Science & Biomedical Policy
  • Norimasa Takeda
    Chief Accounting Officer & Corporate Controller
  • Mr. Iwaaki Taniguchi
    Senior Vice President of Corporate Finance & Controlling Department
  • Mr. Gabriele Ricci (Age 45)
    Chief Data & Technology Officer
  • Mr. Christopher David O'Reilly
    Global Head of Investor Relations & Global Finance

Key Competitors

View All Competitors

Institutional Ownership

View All Institutional Transactions

Should I Buy Takeda Pharmaceutical Stock? TAK Pros and Cons Explained

These insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms. This analysis of Takeda Pharmaceutical was last updated on Tuesday, November 28, 2023 at 9:24 AM.

Pros

Here are some ways that investors could benefit from investing in Takeda Pharmaceutical Company Limited:

  • Takeda Pharmaceutical Company Limited is engaged in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in various areas such as gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience. This diverse product portfolio provides potential for revenue growth and market expansion.
  • The company has a net margin of 7.35% and a return on equity of 12.36%, indicating a healthy financial performance.
  • Analysts predict that Takeda Pharmaceutical Company Limited will post 0.4 earnings per share for the current year, suggesting potential profitability for investors.
  • Takeda Pharmaceutical Company Limited has collaborations and licensing agreements with various reputable companies and research institutions, which can lead to innovative product developments and market opportunities.
  • The company has a strong international presence, allowing it to tap into global markets and potentially benefit from favorable economic conditions in different regions.

Cons

Investors should be bearish about investing in Takeda Pharmaceutical Company Limited for these reasons:

  • The target price on shares of Takeda Pharmaceutical was lowered by JPMorgan Chase & Co., indicating potential concerns about the company's stock performance.
  • Investing in the pharmaceutical industry carries inherent risks, including regulatory challenges, patent expirations, and competition from other companies. These factors can impact the company's revenue and profitability.
  • Fluctuations in currency exchange rates can affect Takeda Pharmaceutical's international operations and financial results.
  • The pharmaceutical industry is subject to evolving market dynamics and changing healthcare policies, which can create uncertainties and impact the company's business strategies.
  • Investors should carefully consider the current stock price and conduct thorough analysis before making investment decisions.














TAK Stock Analysis - Frequently Asked Questions

Should I buy or sell Takeda Pharmaceutical stock right now?

2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Takeda Pharmaceutical in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" TAK shares.
View TAK analyst ratings or view top-rated stocks.

What is Takeda Pharmaceutical's stock price target for 2024?

2 brokers have issued 1 year target prices for Takeda Pharmaceutical's stock. Their TAK share price targets range from $14.00 to $30.00. On average, they predict the company's stock price to reach $21.33 in the next twelve months. This suggests a possible upside of 53.0% from the stock's current price.
View analysts price targets for TAK or view top-rated stocks among Wall Street analysts.

How have TAK shares performed in 2023?

Takeda Pharmaceutical's stock was trading at $15.60 at the beginning of the year. Since then, TAK stock has decreased by 10.6% and is now trading at $13.94.
View the best growth stocks for 2023 here.

When is Takeda Pharmaceutical's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, February 1st 2024.
View our TAK earnings forecast.

How were Takeda Pharmaceutical's earnings last quarter?

Takeda Pharmaceutical Company Limited (NYSE:TAK) announced its quarterly earnings data on Thursday, October, 26th. The company reported $0.50 earnings per share for the quarter. The company earned $6.94 billion during the quarter. Takeda Pharmaceutical had a trailing twelve-month return on equity of 12.36% and a net margin of 7.35%.

Is Takeda Pharmaceutical a good dividend stock?

Takeda Pharmaceutical (NYSE:TAK) pays an annual dividend of $0.25 per share and currently has a dividend yield of 1.79%. The dividend payout ratio is 34.72%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, TAK will have a dividend payout ratio of 52.08% next year. This indicates that the company will be able to sustain or increase its dividend.

What ETFs hold Takeda Pharmaceutical's stock?

ETFs with the largest weight of Takeda Pharmaceutical (NYSE:TAK) stock in their portfolio include VanEck Pharmaceutical ETF (PPH), ActivePassive International Equity ETF (APIE), B.A.D. Etf (BAD) and First Trust International IPO ETF (FPXI).ETFMG Treatments Testing and Advancements ETF (GERM).

What other stocks do shareholders of Takeda Pharmaceutical own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Takeda Pharmaceutical investors own include Cisco Systems (CSCO), Johnson & Johnson (JNJ), Alibaba Group (BABA), Pfizer (PFE), Verizon Communications (VZ), AbbVie (ABBV), CVS Health (CVS), Gilead Sciences (GILD), AT&T (T) and Abbott Laboratories (ABT).

Who are Takeda Pharmaceutical's major shareholders?

Takeda Pharmaceutical's stock is owned by a number of institutional and retail investors. Top institutional investors include Morgan Stanley (0.17%), FMR LLC (0.08%), Northern Trust Corp (0.07%), Brandes Investment Partners LP (0.06%), Managed Asset Portfolios LLC (0.05%) and Envestnet Asset Management Inc. (0.05%).

How do I buy shares of Takeda Pharmaceutical?

Shares of TAK stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

Does Takeda Pharmaceutical have any subsidiaries?
The following companies are subsidiares of Takeda Pharmaceutical: ARIAD Pharmaceuticals, Baxalta Manufacturing S.à r.l., IDM Pharma Inc., Intellikine, Inviragen, LigoCyte Pharmaceuticals, Meritage Pharma Inc., Millennium Pharmaceuticals, Millennium Pharmaceuticals Inc., Nihon Pharmaceutical Co. Ltd., Nycomed Pharma, PvP Biologics, Shire, Shire ViroPharma LLC, Takeda (China) Holdings Co. Ltd., Takeda AS, Takeda Austria GmbH, Takeda Bio Development Center, Takeda California Inc., Takeda Consumer Healthcare Company Limited, Takeda Development Center Americas Inc., Takeda Development Center Asia Pte. Ltd., Takeda Development Centre Europe Ltd., Takeda Distribuidora Ltda., Takeda France S.A.S., Takeda GmbH, Takeda Ireland Limited, Takeda Italia S.p.A., Takeda Pharma A/S, Takeda Pharmaceutical (China) Company Limited, Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals Korea Co. Ltd., Takeda Pharmaceuticals Limited Liability Company, Takeda Pharmaceuticals U.S.A. Inc., Takeda UK Limited, Takeda Vaccines Inc., Takeda Vaccines Pte. Ltd., and TiGenix.
Read More
This page (NYSE:TAK) was last updated on 12/7/2023 by MarketBeat.com Staff

My Account -